These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 25230720)
1. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Italiano D; Bianchini E; Ilardi M; Cilia R; Pezzoli G; Zanettini R; Vacca L; Stocchi F; Bramanti P; Ciurleo R; Di Lorenzo G; Polimeni G; de Luise C; Ross D; Rijnbeek P; Sturkenboom M; Trifirò G J Neural Transm (Vienna); 2015 Jun; 122(6):799-808. PubMed ID: 25230720 [TBL] [Abstract][Full Text] [Related]
2. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Ooba N; Yamaguchi T; Kubota K Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505 [TBL] [Abstract][Full Text] [Related]
3. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285 [TBL] [Abstract][Full Text] [Related]
4. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699 [TBL] [Abstract][Full Text] [Related]
5. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289 [TBL] [Abstract][Full Text] [Related]
6. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Tan T; Cabrita IZ; Hensman D; Grogono J; Dhillo WS; Baynes KC; Eliahoo J; Meeran K; Robinson S; Nihoyannopoulos P; Martin NM Clin Endocrinol (Oxf); 2010 Sep; 73(3):369-74. PubMed ID: 20550538 [TBL] [Abstract][Full Text] [Related]
7. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Antonini A; Poewe W Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566 [TBL] [Abstract][Full Text] [Related]
8. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease. Levin J; Neudert J; Zwermann L; Näbauer M; Bötzel K J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724 [No Abstract] [Full Text] [Related]
9. Dopamine agonists and the risk of cardiac-valve regurgitation. Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453 [TBL] [Abstract][Full Text] [Related]
10. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978 [TBL] [Abstract][Full Text] [Related]